Exemestane Versus Anastrozole in Postmenopausal Women With Early Breast Cancer: NCIC CTG MA.27—A Randomized Controlled Phase III Trial
Paul E. Goss(Princess Margaret Hospital), Lois E. Shepherd(Ontario Institute for Cancer Research), Pedro Emanuel Rubini Liedke(Massachusetts General Hospital), G. Thomas Budd(Cleveland Clinic), Haji Chalchal, Catherine Elliott, Kathleen I. Pritchard, Vered Stearns(Johns Hopkins University), Matthew J. Ellis(Guardant (United States)), Edith A. Perez(Unknown), George W. Sledge(Caris Life Sciences (United States)), Manuela Rabaglio(University Hospital of Bern), Karen A. Gelmon(University of British Columbia), David D’Souza(London Cancer), James N. Ingle(Mayo Clinic), Judy-Anne W. Chapman(Indiana Cancer Consortium), István Láng(National Institute of Oncology), Silvana Spadafora(Sault Area Hospital), Richard Tozer, Rafat Ansari, David B. Johnson(Eastern Virginia Medical School)
Cited by 261
Related Papers
<i>K-ras</i> Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer
|New England Journal of Medicine|2008|3.6k
Palbociclib and Letrozole in Advanced Breast Cancer
|New England Journal of Medicine|2016|2.9k
Tumor Microsatellite-Instability Status as a Predictor of Benefit from Fluorouracil-Based Adjuvant Chemotherapy for Colon Cancer
|New England Journal of Medicine|2003|2.1k
3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
|Annals of Oncology|2016|2.1k